Saturday, October 17, 2026
Accelerating medical breakthroughs to patients
Understand new treatments and trials: who they may help, what the evidence shows, and how access differs by country.
Show treatments for
FDA ApprovedUnited States, China
Beqalzi (sonrotoclax) — oral BCL-2 inhibitor for R/R mantle cell lymphoma after ≥2 lines including a BTK inhibitor
This is for adults with relapsed or refractory mantle cell lymphoma who have already had at least two systemic treatments, including a BTK inhibitor, and who may be candidates for a labelled US oral BCL-2 tablet with a structured dose ramp-up.
New treatments and trials, weekly. Every email has an unsubscribe link.
By subscribing, you request Breakthrough Brief emails. Privacy
Special series
Shots, pills, and organ labels in the 2026 weight class — Wegovy injection, Zepbound, the oral maze, and the process line that authorized is not funded. International by default. Zoom by country. Authorized is not funded.
Treatment types